GuyW.TillinghastMD

PubMed

• 65 citations
  Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.
  John D. Hainsworth, Kent C. Shih, Gregg C. Shepard, Guy W Tillinghast, Brett T Brinker
  Clinical Advances in Hematology & Oncology. 2012-04-01
• 12 citations
  Microarrays in the clinic.
  Guy W Tillinghast
  Nature Biotechnology. 2010-08-01
• 25 citations
  Analysis of genetic stability at the EP300 and CREBBP loci in a panel of cancer cell lines
  Guy W. Tillinghast, Jason Partee, Paul S. Albert, Jenny M. Kelley, Kenneth H. Burtow
  Genes, Chromosomes & Cancer. 2003-06-01

Journal Articles

• Phase II Study of Gemcitabine and Bevacizumab as First-line Treatment in Taxane-pretreated, HER2-negative, Locally Recurrent or Metastatic Breast Cancer  
  Borson R, Harker G, Reeves J, Beck T, Hager S, Horvath W, Jones M, Tillinghast G, Arrowsmith E, Harrer G, Kudrik FJ, Malamud SC, Bromund J, Zeigler H, Tai DF, Kornberg..., Clin Breast Cancer, 1/1/2012
• Phase II Study of Concurrent Radiation Therapy, Temozolomide, and Bevacizumab Followed by Bevacizumab/everolimus as First-line Treatment for Patients with Glioblastoma  
  Hainsworth JD, Shih KC, Shepard GC, Tillinghast GW, Brinker BT, Spigel DR, Clin Adv Hematol Oncol, 1/1/2012
• PPARg Expression Correlates with Differentiated Colon Tumor Lines  
  Tillinghast, G.W. and Segal, S., Proceedings of the American Association for Cancer Research, 1/1/1997

Lectures

• Cancer Statistics 
  Blackstone, Virginia - 9/14/2004
• Cancer Management 
  Blackstone, Virginia - 9/14/2004
• Supportive Care 
  Blackstone, Virginia - 9/14/2004